Goldman Sachs Amends Rhythm Pharma Stake; Ownership Update Filed
Ticker: RYTM · Form: SC 13G/A · Filed: Feb 5, 2024 · CIK: 1649904
| Field | Detail |
|---|---|
| Company | Rhythm Pharmaceuticals, Inc. (RYTM) |
| Form Type | SC 13G/A |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**Goldman Sachs updated its Rhythm Pharma stake, watch for potential shifts in institutional sentiment.**
AI Summary
Goldman Sachs Group Inc. filed an amended SC 13G/A on February 5, 2024, indicating a change in their beneficial ownership of Rhythm Pharmaceuticals, Inc. common stock as of December 29, 2023. This update, filed under Rule 13d-1(b), signals that Goldman Sachs continues to hold a significant, though potentially adjusted, stake in the pharmaceutical company. For investors, this matters because large institutional holdings by firms like Goldman Sachs can influence stock stability and market perception, suggesting a level of confidence in Rhythm Pharmaceuticals' future, or a shift in that confidence.
Why It Matters
This filing shows that a major financial institution, Goldman Sachs, is still a significant holder of Rhythm Pharmaceuticals stock, which can be seen as a vote of confidence or a signal of their ongoing investment strategy.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor and doesn't inherently signal high risk, but rather a change in their reported holdings.
Analyst Insight
An investor should monitor subsequent filings from Goldman Sachs to track any further changes in their ownership percentage, as significant increases or decreases could signal a shift in their investment thesis for Rhythm Pharmaceuticals.
Key Numbers
- 76243J105 — CUSIP Number (identifies the specific class of securities (Common Stock of Rhythm Pharmaceuticals, Inc.).)
- 005-90134 — SEC File Number (identifies Rhythm Pharmaceuticals, Inc.'s registration with the SEC.)
Key Players & Entities
- Goldman Sachs Group Inc. (company) — the entity filing the SC 13G/A, reporting its ownership in Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals, Inc. (company) — the subject company whose common stock is being reported on.
- December 29, 2023 (date) — the date of the event which required the filing of this statement.
- $0.001 (dollar_amount) — the par value per share of Rhythm Pharmaceuticals, Inc. common stock.
Forward-Looking Statements
- Goldman Sachs will continue to be a significant institutional holder of Rhythm Pharmaceuticals stock. (Goldman Sachs Group Inc.) — medium confidence, target: next 12 months
FAQ
What type of filing is this and who filed it?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G, filed by Goldman Sachs Group Inc. regarding its ownership in Rhythm Pharmaceuticals, Inc.
What is the specific date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 29, 2023.
Under which SEC rule was this Schedule 13G/A filed?
This Schedule 13G/A was filed under Rule 13d-1(b) of the Securities Exchange Act of 1934.
What is the par value of Rhythm Pharmaceuticals, Inc.'s common stock?
The common stock of Rhythm Pharmaceuticals, Inc. has a par value of $0.001 per share.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Rhythm Pharmaceuticals, Inc. is 76243J105.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 5, 2024 regarding RHYTHM PHARMACEUTICALS, INC. (RYTM).